TXG Stock Chart & Stats
$335.54
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$150.00 - $363.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$102.71B
Enterprise Value$2.27K
Total Cash (Recent Filing)$539.85M
Total Debt (Recent Filing)$81.39M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 06, 2026EPS Estimate
-4.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding116,877,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.56
Price to Sales (P/S)3.17
P/FCF Ratio15.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-14.01
Revenue Forecast (FY)$10.67B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthRecurring consumables growth demonstrates the stickiness of 10x's platform model: instruments drive an installed base and consumables generate repeat, usage-driven revenue. Double-digit spatial growth and rising reaction volumes support durable per-customer monetization and long-term revenue leverage from installed instruments.
Improved Cash Generation And MarginsPositive operating and free cash flow combined with high gross margins underpin financial resilience: strong cash conversion funds R&D, inventory and production scaling without needing material new leverage, enabling sustained investment in assays and platform enhancements over the medium term.
Product Leadership & Strategic Partnerships (Atara Launch)Atara and complementary partnerships expand the company’s addressable market and strengthen differentiation. A scalable, upgradable spatial platform plus collaborations that drive large biological datasets create durable competitive advantages and position 10x as a preferred data generator for translational and AI-driven biology initiatives.
Bears Say
Sharp Trailing Revenue DeclineA very large TTM revenue decline signals structural demand or timing issues that can pressure operating leverage. Even with improving margins and cash, a steep top-line contraction limits sustainable profit expansion and increases sensitivity to execution on new product ramps and consumables adoption.
Instrument Revenue WeaknessA sizable drop in instrument placements reduces the long-term growth engine for consumables and slows installed-base expansion. Delays in capital purchases indicate customer timing risk and can create multi-quarter headwinds to recurring revenue buildup even if consumables momentum eventually resumes.
Limited Initial Atara Capacity & Margin Mix RiskConstrained early production reduces the near-term revenue and consumables pull-through from Atara, delaying the payback on R&D and manufacturing investment. Lower instrument margins and mix shifts toward lower-margin units could pressure overall gross margins as volumes scale, complicating margin sustainability.
TXG FAQ
What was 10X Genomics’s price range in the past 12 months?
10X Genomics lowest stock price was $150.00 and its highest was $363.00 in the past 12 months.
What is 10X Genomics’s market cap?
10X Genomics’s market cap is $102.71B.
When is 10X Genomics’s upcoming earnings report date?
10X Genomics’s upcoming earnings report date is Aug 06, 2026 which is in 11 days.
How were 10X Genomics’s earnings last quarter?
10X Genomics released its earnings results on May 07, 2026. The company reported -$1.751 earnings per share for the quarter, beating the consensus estimate of -$4.815 by $3.064.
Is 10X Genomics overvalued?
According to Wall Street analysts 10X Genomics’s price is currently Undervalued.
Does 10X Genomics pay dividends?
10X Genomics does not currently pay dividends.
What is 10X Genomics’s EPS estimate?
10X Genomics’s EPS estimate is -4.25.
How many shares outstanding does 10X Genomics have?
10X Genomics has 116,877,320 shares outstanding.
What happened to 10X Genomics’s price movement after its last earnings report?
10X Genomics reported an EPS of -$1.751 in its last earnings report, beating expectations of -$4.815. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of 10X Genomics?
Currently, no hedge funds are holding shares in MX:TXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
10x Genomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
MX:TXG Sentiment 50%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $19.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
252.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.44%
Trailing 12-Months
Company Description
10X Genomics
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.